

01/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Class: Subclass:

Art Unit: 1631

"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: BOX PATENT APPLICATION FEE, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

TYPED NAME: Lisa Jeanetta

SIGNED

Assistant Commissioner for Patents
Washington, DC 20231

Sine

This is a request for filing an

Original

X Continuation

Divisional

Continuation-in-part

application under 37 C.F.R. 1.53(b), in the name of Garry P. Nolan and S. Michael Rothenberg, for Methods for Screening for Transdominant Effector Peptides and RNA Molecules. This X continuation divisional continuation-in-part claims priority to pending application Serial No. 08/589,109, filed on January 23, 1996.

1. (a) ☐ Enclosed is a new application.
(b) ☐ Enclosed is a continuation-in-part application.
(c) ☒ Enclosed is a copy of the prior application.
2. (a) ☐ Enclosed is a new Declaration.
(b) ☒ Enclosed is a copy of the prior executed Declaration as originally filed.
(c) ☐ Enclosed is a Combined Declaration/Power of Attorney.
3. Applicant is a small entity.

4. X The filing fee is calculated below: Claims as filed in the prior application, less any claims canceled by amendment below:

	(Col. 1)	(Col.2)	<u>SMALL ENTITY</u>			<u>OTHER THAN A SMALL ENTITY</u>	
For:	<u>No. Filed</u>	<u>No. Extra</u>	<u>Rate</u>	<u>Fee</u>	<u>Or</u>	<u>Rate</u>	<u>Fee</u>
Basic Fee				\$370.00			\$740.00
Total Claims	<u>7</u> - 20 =	<u>0</u>	<u> </u> x 9 =	\$ <u> </u>	OR	<u> </u> x \$18 =	\$ <u> </u>
Indep Claims	<u> </u> - 3 =	<u> </u>	<u> </u> x 40 =	\$ <u> </u>	OR	<u> </u> x \$80 =	\$ <u> </u>
[] Multiple Depen Claims			+ \$135 =	\$ <u> </u>	OR	+ \$270 =	\$ <u> </u>
Total							<u>\$370.00</u>

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

5. X The Commissioner is hereby authorized to charge any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 06-1300 (Order No. A64259-2/RMS/AMS).
6. X A check for \$ 370.00 is enclosed to pay the fees.
7. Cancel in this application original claims of the prior application before calculating the filing fee. (At least one independent claim must be retained for filing purposes.)
8. X Amend the specification by inserting before the first line the sentence:
--This is a continuation of application U.S. Serial No. 08/589,109, filed on January 23, 1996.
9. (a) X Informal drawings are enclosed, 4 sheets.
(b) Formal drawings are enclosed, sheets.
10. (a) Priority of provisional application Serial No. filed on in is claimed under 35 U.S.C. 119.
(b) The certified copy has been filed in prior application Serial No. filed on .
11. An Assignment is enclosed.
12. X The prior application is assigned of record to Board of Trustees of the Leland Stanford Junior University and Rigel Pharmaceuticals, Inc.
13. X The power of attorney in the prior application is to:


FLEHR HOHBACH TEST ALBRITTON & HERBERT, LLP

- (a) X The power appears in the original papers in the prior application.
- (b) Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c) X Address all future communications to:

Robin M. Silva
FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187
Telephone: (415) 781-1989

14. A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)
15. A Prior Art Statement is enclosed.
16. X I hereby verify that the attached papers are a true duplicate of prior application Serial No. 08/589,109 as originally filed on January 23, 1996.

Date: January 22, 2002


Robin M. Silva
Registration No. 38,304

Address of Signer:

X Attorney or agent of record

Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187
Telephone: 415-781-1989

 Filed under Section 1.34(a)

1073038